Langerhans Cell Histiocytosis (LCH)

Langerhans Cell Histiocytosis (LCH) is a rare disorder that affects the body's immune system, specifically the Langerhans cells, which are a type of white blood cell involved in fighting infections. In this condition, these cells grow abnormally and can form tumors or lesions in various parts of the body, including the bones, skin, and sometimes organs like the lungs or liver. The disease mainly impacts the skeletal system but can also cause skin rashes and other symptoms depending on the organs involved. It can affect both children and adults, with symptoms ranging from mild to severe. The abnormal cell growth can lead to pain, swelling, and damage to affected tissues, which may interfere with normal body functions.

Langerhans Cell Histiocytosis (LCH) is a clonal proliferative disorder characterized by the accumulation of pathologic Langerhans cells, which are dendritic cells normally involved in antigen presentation. The disease results from somatic mutations, frequently involving the BRAF V600E mutation, leading to uncontrolled cell growth and infiltration of tissues. LCH can present as a single-system or multisystem disease, with common involvement of the bone, skin, lymph nodes, and occasionally the lungs and pituitary gland. The clinical significance lies in its potential to cause destructive lesions, organ dysfunction, and systemic symptoms such as fever and weight loss. Histologically, the lesions contain Langerhans cells with characteristic Birbeck granules visible on electron microscopy. Diagnosis and management require multidisciplinary care due to the variable clinical course and potential for chronic complications.